Inflammation and Coagulation: Implications for the Septic Patient
Open Access
- 15 May 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (10), 1259-1265
- https://doi.org/10.1086/374835
Abstract
Sepsis with acute organ dysfunction (severe sepsis) is common, frequently fatal, and associated with a significant national health/economic burden. IKeywords
This publication has 71 references indexed in Scilit:
- Pretreatment with tumor necrosis factor-α attenuates arterial hypotension and mortality induced by endotoxin in pigsCritical Care Medicine, 2000
- E5 Murine Monoclonal Antiendotoxin Antibody in Gram-Negative SepsisA Randomized Controlled TrialJAMA, 2000
- New Concepts in Activation of the Clotting Cascade in SepsisSepsis, 1999
- Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shockThe Lancet, 1998
- p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study GroupPublished by American Medical Association (AMA) ,1997
- Sir Isaac Newton, sepsis, SIRS, and CARSCritical Care Medicine, 1996
- Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion ProteinNew England Journal of Medicine, 1996
- ALTERATIONS IN COAGULATION AND FIBRINOLYSIS DURING SEPSISShock, 1996
- Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study GroupPublished by American Medical Association (AMA) ,1995
- Treatment of Septic Shock with Human Monoclonal Antibody HA-1AAnnals of Internal Medicine, 1994